Prognose

Für dieses Unternehmen liegen uns keine Analysten-Daten vor.

Scoring-Modelle

Dividenden-Strategie	0 / 15
HGI-Strategie	0 / 18
Levermann-Strategie	-4 / 13

News

Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on May 19, 2025 (the "Notice"). The Notice indicated that the Nasdaq Hearings Panel (the “Panel”) will consider the Company's failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025 as an additional basis for delisting the Company's securities from The Nasdaq Stock Market.» Mehr auf globenewswire.com
Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K
CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on April 24, 2025 (the "Notice"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c) (the “Listing Rule”) as a result of its failure to timely file its Annual Report on Form 10-K for the annual period ended December 31, 2024 (the “2024 Form 10-K”), as described more fully in the Company's Form 12b-25 Notification of Late Filing (the “Form 12b-25”) filed with the Securities and Exchange Commission (the "SEC") on April 1, 2025. The Listing Rule requires Nasdaq-listed companies to timely file all required periodic reports with the SEC.» Mehr auf globenewswire.com
Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)
New York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of private placement of 5,100 Series A-2 Preferred Shares, with a stated value of US$1,000 per share, for its client Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (“Qualigen” or the “Company”), a life science company focused on developing platform treatments for adult and pediatric cancers, with the potential for orphan drug designations.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Qualigen Therapeutics einen Umsatz von 0,00€ und ein Nettoeinkommen von −1,61 Mio€

(EUR)	Sep. 2024	YOY
Umsatz	0,00	-
Bruttoeinkommen	0,00	-
Nettoeinkommen	−1,61 Mio	-
EBITDA	−1,25 Mio	-

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+2,23 Mio€
Anzahl Aktien	736,43k
52 Wochen-Hoch/Tief	+25,13€ - +2,43€
Dividenden	Nein
Beta	0,03
KGV (PE Ratio)	−0,17
KGWV (PEG Ratio)	0,00
KBV (PB Ratio)	−0,63
KUV (PS Ratio)	0,00

Unternehmensprofil

Qualigen Therapeutics, Inc. ist ein Biotechnologieunternehmen, das neuartige therapeutische Produkte für die Behandlung von Krebs und Infektionskrankheiten entwickelt. Es bietet FastPack, ein diagnostisches Schnelltestsystem, an. Das Unternehmen entwickelt QN-302 für die Behandlung des duktalen Adenokarzinoms der Bauchspeicheldrüse, QN-247, einen Krebsmedikamentenkandidaten mit DNA-beschichteten Goldnanopartikeln, der auf verschiedene Krebsarten abzielt, RAS-F, einen niedermolekularen RAS-Onkogen-Protein-Protein-Inhibitor, der RAS-Mutationen blockiert und die Tumorbildung hemmt, und STARS Blutreinigungssystem, ein DNA/RNA-basiertes Behandlungsgerät, das tumorproduzierte Verbindungen und Viren aus dem Blut eines Patienten entfernt. Qualigen Therapeutics, Inc. wurde 1996 gegründet und hat seinen Sitz in Carlsbad, Kalifornien.